Previous 10 | Next 10 |
Achieved Record Total Revenues of $17.8 Million in Second Quarter 2021, a 129% Increase Over Second Quarter 2020 Narrowed Gross and Net Losses Year-over-Year ADMA Now Anticipates Exiting 2021 Approaching an Annualized Revenue Run Rate of Approximately $100 Million or Mor...
RAMSEY, N.J. and BOCA RATON, Fla. and CONYERS, Ga., Aug. 10, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, annou...
ADMA Expands Commercial IG Product Offering with Additional BIVIGAM and NABI-HB Vial Sizes BIVIGAM 100 mL Vial and NABI-HB 1 mL Vial Now Commercially Available to U.S. Healthcare Providers RAMSEY, N.J. and BOCA RATON, Fla., Aug. 09, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, I...
RAMSEY, N.J. and BOCA RATON, Fla., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived bi...
Approval for VanRx Fill-Finish Machine Expected in the Second Half of 2021 All Supply Chain Robustness Initiatives Remain on Schedule RAMSEY, N.J. and BOCA RATON, Fla., July 20, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-...
Shares of ADMA Biologics Inc (NASDAQ:ADMA) traded today at $1.39, breaking its 52-week low. Approximately 315,000 shares have changed hands today, as compared to an average 30-day volume of 2.4 million shares. ADMA Biologics Inc has overhead space with shares priced $1.44, or 22.3% below...
alexsl/iStock via Getty Images ADMA Biologics (ADMA) has extended its five-day long losing streak for the sixth trading session while H.C. Wainwright cut its price target to $7.00 from $10.00 per share, implying a premium of ~363.6% to the close. Maintaining the buy rating, the analyst Raghur...
At the conclusion of the 2021 Russell indexes annual reconstitution following notable healthcare stocks will join the Russell 3000 Index, effective June 28 after the U.S. market opens.Bionano Genomics (BNGO), Asensus Surgical (ASXC), Ocugen (OCGN), Senseonics Holdings (SEN...
RAMSEY, N.J. and BOCA RATON, Fla., June 14, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced...
RAMSEY, N.J. and BOCA RATON, Fla., May 26, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced ...
News, Short Squeeze, Breakout and More Instantly...
2024-05-10 11:30:04 ET Raymond James analyst issues STRONG BUY recommendation for ADMA on May 10, 2024 09:52AM ET. The previous analyst recommendation was Strong Buy. ADMA was trading at $8.705 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...